Frexalimab

Sanofi's frexalimab is an Fc-silenced anti-CD40L monoclonal antibody that blocks the CD40-CD40L costimulatory handshake driving B-cell and T-cell activation in autoimmune disease. The Phase 2 readout in relapsing MS showed an 89% reduction in new gadolinium-enhancing brain lesions at 12 weeks versus placebo [1] - among the strongest Phase 2 MRI signals from any non-depleting mechanism, though natalizumab (an integrin blocker, also non-depleting) showed ~92% Gd+ lesion reduction over 2 years in Phase 3 AFFIRM [10], so this is not a unique superlative. Two Phase 3 trials in MS - FREXALT in relapsing forms (NCT06141473, n=1655) [2] and FREVIVA in non-relapsing secondary progressive (NCT06141486, n=943) [3] - are in active execution, with primary completion targeted around mid-2027. Frexalimab also has Phase 2 programs in type 1 diabetes [4] and kidney transplantation [5], making it Sanofi's most strategically important pipeline biologic outside oncology - though Sanofi's own tolebrutinib BTK inhibitor complicates the SPMS commercial case [9].

Frexalimab is a novel biologic - no anti-CD40L antibody has ever been approved for any indication. The compound carries no FDA breakthrough or fast track designation as of mid-2026. Phase 2 in relapsing MS read out in early 2024 with positive lesion data [1], and the program moved into two Phase 3 trials: FREXALT (NCT06141473) in relapsing forms (n=1655, annualized relapse rate vs teriflunomide primary endpoint) [2] and FREVIVA (NCT06141486) in non-relapsing secondary progressive MS (n=943, time-to-confirmed-disability-progression vs placebo) [3]. Sanofi has not publicly confirmed enrollment closure for either trial; AAN 2026 presentations described the program as ongoing without enrollment confirmation, and FREVIVA site listings as of mid-2026 still show active recruitment. Sanofi has not formally guided to a Phase 3 readout date, but ClinicalTrials.gov primary completion estimates point to 2027-2028 top-line data. Beyond MS, Sanofi has opened Phase 2 trials in type 1 diabetes (FABULINUS, NCT06111586, n=192, C-peptide preservation primary) [4] and Phase 2 versus tacrolimus in kidney transplantation (NCT07412470, n=526) [5]. A Phase 3 subcutaneous-versus-intravenous bioequivalence study is recruiting 160 patients [6], a near-mandatory step for any MS drug given how badly patients tolerate quarterly infusion-center visits compared to home injection.

CD40 ligand (CD40L, also called CD154) sits on activated T cells. When CD40L grabs onto CD40 on B cells, dendritic cells, and macrophages, it delivers a 'second signal' - the costimulation that licenses T cells to fully activate and B cells to class-switch into antibody-producing and inflammatory subsets. Block this handshake and you dampen both arms of adaptive immunity without depleting any cell type, unlike anti-CD20 antibodies (Ocrevus, Kesimpta) which kill B cells outright. The genetics validate the target hard: humans born with loss-of-function mutations in CD40LG get hyper-IgM syndrome, an inherited immunodeficiency where B cells cannot class-switch and patients are vulnerable to opportunistic infection (Open Targets evidence score 0.85). That tells you the pathway is real and biologically load-bearing. The catch, and it's a big one, is that the first generation of anti-CD40L antibodies in the late 1990s (Biogen's hu5c8/ruplizumab) caused thromboembolic events because CD40L is also on platelets and antibody Fc crosslinking activated platelet aggregation. Frexalimab is engineered with a silenced Fc region to avoid that platelet crosslinking [1]. The Fc region is the antibody's tail that normally flags targets for immune attack via Fc-gamma receptors on platelets and immune effector cells - 'silencing' it (via point mutations that abolish FcγR binding) means the antibody can block CD40L without simultaneously crosslinking platelets into clot-promoting aggregates. Phase 2 data so far show no thromboembolic signal. Whether that holds across the ~2,600 patients in Phase 3 is the question that will define the entire CD40L mechanism going forward.

The lead Phase 3 in relapsing MS (FREXALT, NCT06141473, n=1655) uses annualized relapse rate versus oral teriflunomide as primary endpoint [2] - the same FDA-accepted comparison that supported Ocrevus, Kesimpta, and every modern MS approval. Teriflunomide sets a moderate efficacy bar; relapse rate reductions of 30-50% versus teriflunomide are typical for high-efficacy agents and define the commercial entry point. The companion trial in non-relapsing SPMS (FREVIVA, NCT06141486, n=943) is the harder swing [3]: primary endpoint is time to confirmed disability progression versus placebo in patients without ongoing relapses, the population where every drug has failed except siponimod (which barely cleared the bar). Note: while we describe this as a '6-month confirmed disability progression' endpoint, Sanofi's public trial documentation specifies a 3-year follow-up window without consistently confirming the CDP confirmation interval; if it is 3-month CDP rather than 6-month, the endpoint is materially easier to hit. Two design choices worth flagging. First, the SPMS study explicitly requires non-relapsing patients, meaning Sanofi avoided the trap of letting relapse-driven progression mask the true disability signal - this is a cleaner test than ocrelizumab's PPMS trial. Second, the relapsing trial's teriflunomide comparator (not placebo) lets payers compare apples-to-apples against a cheap generic, which matters for the eventual price negotiation. The subcutaneous bioequivalence Phase 3 (NCT07325292, n=160) measures PK comparability over a 4-week window [6], essential because the current IV every-4-weeks route is a commercial dead end against Ocrevus's twice-yearly dosing and Kesimpta's monthly SC self-injection.

The model gives this drug an 8% chance of eventually being approved. That starts from a historical baseline of about 24% for Phase 2 drugs in this area, then adjusts based on ten facts about the trial and the sponsor. The sponsor's track record of getting drugs approved pushes the number up, while heavier-than-usual blinding, weak earlier-phase results, and a randomized design pull it back down. The remaining factors fall close to average for this stage and leave the estimate roughly where the baseline set it.

The lurking concern is thromboembolic safety. The first generation of anti-CD40L antibodies failed because CD40L on platelets, when crosslinked by an Fc-competent antibody, triggers aggregation and clotting. Frexalimab's silenced Fc is the engineering fix, and Phase 1 and 2 data show no thromboembolic signal [1]. But the Phase 3 pool is roughly 10x larger and rare safety events surface at scale. A second-tier risk is infection: blocking T-cell-B-cell help impairs response to novel pathogens and vaccines. Frexalimab will need to show this is not worse than ocrelizumab, which already carries warnings about reduced vaccine response and a low PML rate. Efficacy risk concentrates in the SPMS arm - the primary endpoint of disability progression in non-relapsing patients is the graveyard of MS drug development [3]. Commercial risk is real even on approval, and the dosing schedule is a meaningful headwind: frexalimab is currently IV every 4 weeks versus Ocrevus every 6 months and Kesimpta monthly self-administered SC. Even if the SC formulation succeeds in PK bioequivalence [6], the dosing frequency for SC frexalimab has not been publicly stated and likely remains more frequent than Ocrevus, eroding convenience parity. The MS market is crowded with anti-CD20 antibodies - Ocrevus is the single-largest MS franchise globally with revenues in the high single-digit billions [8], and Kesimpta is growing share rapidly. Frexalimab must show either better efficacy, better safety (no PML or infection signal), or a meaningfully different mechanism story to carve out share. Portfolio cannibalization is the critical internal risk: Sanofi's own tolebrutinib reportedly hit its primary endpoint in non-relapsing SPMS in the HERCULES Phase 3 readout discussed publicly in 2024-2025 [9]; if tolebrutinib lands an SPMS approval before FREVIVA reads out, Sanofi has limited incentive to actively promote frexalimab in the same population, and the SPMS arm becomes commercially academic regardless of trial outcome. Execution risk also includes the SC bioequivalence study failing PK comparability - without an SC option, frexalimab is a much smaller commercial story.

Worth watching seriously. Frexalimab is the most credible test of a non-depleting MS mechanism since fingolimod, and Sanofi clearly views it as a flagship neuroinflammation asset - company revenue was roughly $51B in 2025 [7], and the MS franchise has been rebuilding since Lemtrada's safety issues and Aubagio's generic erosion. The signal to wait for is Phase 3 top-line FREXALT (relapsing MS) data, expected in the 2027-2028 window per ClinicalTrials.gov primary completion estimates. Check back when Sanofi pre-announces the readout date, usually 6-9 months in advance via R&D day or quarterly call. The three data points that matter: (1) annualized relapse rate versus teriflunomide - anything above 40% reduction is competitive, above 50% is class-leading and worth a real premium; (2) any thromboembolic signal at all, even single-digit events, is a stock-mover and a mechanism-killer; (3) MRI lesion data, where the Phase 2 89% reduction sets a high bar Sanofi must defend at scale [1]. Portfolio prioritization is the underappreciated wrinkle: if tolebrutinib carries SPMS approval into the FREVIVA readout window, Sanofi rationally directs its MS commercial muscle behind the oral BTK inhibitor in that population and lets frexalimab carry the relapsing MS load. That collapses the frexalimab revenue case to roughly the relapsing MS opportunity alone - still a $1-2B drug competing against Ocrevus [8] if it hits, but not the multi-billion-dollar pan-MS franchise the dual-trial design implies. Patent cliff considerations matter for long-term modeling: as a biologic, frexalimab faces biosimilar exposure roughly 12-13 years post-approval, so a 2028-2029 approval implies meaningful exclusivity into the late 2030s - material for any pharma DCF. If both Phase 3 trials hit and safety holds, this is a multi-billion-dollar MS franchise with real optionality into T1D [4] and transplant [5]. If the SPMS trial misses but relapsing MS wins, it is still a $1-2B drug. If safety unwinds, the entire CD40L mechanism is dead for another decade. The relapsing MS readout is the binary event.